Aspire Biopharma (NASDAQ:ASBP) Posts Earnings Results

Aspire Biopharma (NASDAQ:ASBP) released its quarterly earnings data on Friday. The company reported ($20.57) earnings per share (EPS) for the quarter, FiscalAI reports. The firm had revenue of $0.03 million for the quarter.

Aspire Biopharma Stock Performance

Shares of NASDAQ ASBP opened at $5.61 on Friday. Aspire Biopharma has a fifty-two week low of $3.31 and a fifty-two week high of $1,050.36. The stock has a market cap of $953,700.00, a price-to-earnings ratio of -0.28 and a beta of 0.21. The firm’s 50-day simple moving average is $20.67 and its 200 day simple moving average is $90.13.

Hedge Funds Weigh In On Aspire Biopharma

Large investors have recently added to or reduced their stakes in the business. CIBC Bancorp USA Inc. bought a new position in Aspire Biopharma in the 3rd quarter valued at about $28,000. Jane Street Group LLC lifted its position in Aspire Biopharma by 625.8% in the 2nd quarter. Jane Street Group LLC now owns 152,552 shares of the company’s stock valued at $41,000 after acquiring an additional 131,533 shares in the last quarter. Finally, XTX Topco Ltd lifted its position in Aspire Biopharma by 853.2% in the 4th quarter. XTX Topco Ltd now owns 265,471 shares of the company’s stock valued at $35,000 after acquiring an additional 237,620 shares in the last quarter. Institutional investors own 19.17% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have recently issued reports on ASBP. Weiss Ratings reissued a “sell (e+)” rating on shares of Aspire Biopharma in a research report on Monday, April 20th. Wall Street Zen raised shares of Aspire Biopharma to a “sell” rating in a research report on Saturday, January 17th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock currently has a consensus rating of “Sell”.

Aspire Biopharma Company Profile

Aspire Biopharma Inc is a specialty pharmaceutical company dedicated to developing and commercializing inhaled therapeutics for cardiopulmonary emergencies and respiratory diseases. The firm leverages proprietary formulation and drug-delivery technologies to repurpose established active pharmaceutical ingredients, aiming to enhance onset of action and improve patient convenience in acute settings. Aspire’s focus on pulmonary administration differentiates its approach from traditional oral or injectable treatments for asthma, allergic reactions, and other respiratory conditions.

The company’s lead asset is a reformulated metered-dose inhaler version of epinephrine designed to serve as an over-the-counter or prescription rescue therapy for acute bronchospasm and anaphylaxis.